[go: up one dir, main page]

AR011610A1 - USE OF 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2-PIRIDINYL] -PIPERACINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITIONAL SALT OF THE SAME, A PHARMACEUTICAL FORMULATION ADAPTED FOR THE TREATMENT OF URINARY INCONTINENCE AND AN URINARY FORMULINATION WHICH INCLUDE SUCH A COMPOUND OR - Google Patents

USE OF 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2-PIRIDINYL] -PIPERACINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITIONAL SALT OF THE SAME, A PHARMACEUTICAL FORMULATION ADAPTED FOR THE TREATMENT OF URINARY INCONTINENCE AND AN URINARY FORMULINATION WHICH INCLUDE SUCH A COMPOUND OR

Info

Publication number
AR011610A1
AR011610A1 ARP980100446A AR011610A1 AR 011610 A1 AR011610 A1 AR 011610A1 AR P980100446 A ARP980100446 A AR P980100446A AR 011610 A1 AR011610 A1 AR 011610A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
urinary
urinary incontinence
treatment
pharmaceutical formulation
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR011610A1 publication Critical patent/AR011610A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de 1-[6-cloro-5-(trifluorometil)-2-piridinil]-piperacina, o una sal de adicion ácida farmacéuticamente aceptable de la misma, donde dicha1-[6-cloro-5-(trifluorometil)-2-piridinil)-2-]-piperacina, o una sal de adicion ácida farmacéuticamente aceptable de la misma es empleada para laelaboracion de un medicamento para el tratamiento o la profilaxis de la incontinencia urinaria. Un método para tratar la incontinencia urinaria enun animal que comprende el tratarlo con una cantidad terapéuticamente efectiva de 1-[-6-cloro-5-(trifluorometil)-2-piridinil]-piperacina, o una salde adicion ácida farmacéuticamente aceptable de la misma. Una formulacion farmacéutica adaptada para el tratamiento de la incontinenciaurinaria, quecomprende 1-[6-cloro-5-(trifluorometil)-2-piridinil]-piperacina, o una sal de adicion ácida farmacéuticamente aceptable de la misma, junto con underivado farmacéuticamente aceptable de la misma. Una formulacion anti- incontinencia urinaria, que comprende 1-[6-cloro-5-(trifluorometil)-2-piridinil]-piperacina, o una sal de adicion ácida de la misma farmacéuticamente aceptable, junto con un derivado farmacéuticamente aceptable para eso.Use of 1- [6-chloro-5- (trifluoromethyl) -2-pyridinyl] -piperazine, or a pharmaceutically acceptable acid addition salt thereof, wherein said 1- [6-chloro-5- (trifluoromethyl) -2- pyridinyl) -2 -] - piperazine, or a pharmaceutically acceptable acid addition salt thereof, is used for the manufacture of a medicament for the treatment or prophylaxis of urinary incontinence. A method of treating urinary incontinence in an animal comprising treating it with a therapeutically effective amount of 1 - [- 6-chloro-5- (trifluoromethyl) -2-pyridinyl] -piperazine, or a pharmaceutically acceptable acid addition salt thereof . A pharmaceutical formulation adapted for the treatment of urinary incontinence, comprising 1- [6-chloro-5- (trifluoromethyl) -2-pyridinyl] -piperazine, or a pharmaceutically acceptable acid addition salt thereof, together with pharmaceutically acceptable underivative of the same. A urinary incontinence formulation, comprising 1- [6-chloro-5- (trifluoromethyl) -2-pyridinyl] -piperazine, or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable derivative therefor.

ARP980100446 1997-02-03 1998-02-02 USE OF 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2-PIRIDINYL] -PIPERACINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITIONAL SALT OF THE SAME, A PHARMACEUTICAL FORMULATION ADAPTED FOR THE TREATMENT OF URINARY INCONTINENCE AND AN URINARY FORMULINATION WHICH INCLUDE SUCH A COMPOUND OR AR011610A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97200285 1997-02-03

Publications (1)

Publication Number Publication Date
AR011610A1 true AR011610A1 (en) 2000-08-30

Family

ID=8227979

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100446 AR011610A1 (en) 1997-02-03 1998-02-02 USE OF 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2-PIRIDINYL] -PIPERACINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITIONAL SALT OF THE SAME, A PHARMACEUTICAL FORMULATION ADAPTED FOR THE TREATMENT OF URINARY INCONTINENCE AND AN URINARY FORMULINATION WHICH INCLUDE SUCH A COMPOUND OR

Country Status (4)

Country Link
AR (1) AR011610A1 (en)
AU (1) AU6619398A (en)
IL (1) IL122975A0 (en)
ZA (1) ZA98531B (en)

Also Published As

Publication number Publication date
IL122975A0 (en) 1998-08-16
ZA98531B (en) 1998-07-17
AU6619398A (en) 1998-08-25

Similar Documents

Publication Publication Date Title
DE69521994D1 (en) COMPOSITIONS WHICH CONTAIN DNA DESTROYING AGENTS AND P53
RU2009112207A (en) SPECIFIC GLUCCORTICOSTEROID COMPOUND WITH ANTI-INFLAMMATORY ACTIVITY
GB2303629B (en) Hydroxamic acids and their use as metalloproteinase inhibitors
SE9301489D0 (en) VETERINARY COMPOSITION
ES2081780T3 (en) NEW ARILPROPIONIC DERIVATIVE, PROCEDURE FOR ITS PREPARATION AND ITS USE AS AN ANALGESIC AGENT.
BRPI0113331B8 (en) phenylalanine derivatives or their pharmaceutically acceptable salts, alpha 4 integrin antagonist, therapeutic agent or preventive agent for inflammatory diseases, and pharmaceutical composition
UY26372A1 (en) "IMIDAZO-3-IL-AMINAS BICÍCLICAS PROCEDURE FOR ITS PREPARATION AND DRUGS THAT CONTAIN THEM"
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
DE69932939D1 (en) FULVIC ACID AND ITS USE FOR THE TREATMENT OF VARIOUS DISEASE STATES
ATE333896T1 (en) VASCULARIZATION INHIBITORS
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
SE9704644D0 (en) New use
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
AR015966A1 (en) USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
SE9603725D0 (en) New teatment
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
BR0007452A (en) Use of melagatran or a pharmaceutically acceptable derivative or prodrug thereof, method of treating inflammation, and, pharmaceutical formulation for use in treating inflammation
NO20042758L (en) Procedure for treating a patient requiring analgesia.
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AR011610A1 (en) USE OF 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2-PIRIDINYL] -PIPERACINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITIONAL SALT OF THE SAME, A PHARMACEUTICAL FORMULATION ADAPTED FOR THE TREATMENT OF URINARY INCONTINENCE AND AN URINARY FORMULINATION WHICH INCLUDE SUCH A COMPOUND OR
PA8519501A1 (en) FARNESIL TRANSFER INHIBITOR OF THE 1,2-RING QUINOLINE DUMPER
BR0017367A (en) Use of melagatran or a pharmaceutically acceptable derivative thereof, method of treating an ischemic disorder in a patient having, or at risk for, nonvalvular atrial fibrillation and pharmaceutical formulation